HOME >> BIOLOGY >> NEWS
Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting

Snowmass, Co. (September 9, 2004) Inflammatory Bowel Diseases, comprised of Crohn's Disease and ulcerative colitis, are for the most part incurable and their causes are still unknown. About 1 million Americans suffer from IBD and research around the world on new therapeutic strategies against IBD is being reported at a conference sponsored by the American Physiological Society.

Below are reports on three presentations.

  • Anti-adhesion therapy in the treatment of IBD Julian Panes and Josep M. Pique of the Gastroenterology Department of the Hospital Clinic Barcelona, Spain, note that the localization for leukocytes to inflammatory areas has key implications in the pathogenesis, diagnosis and treatment of IBD. A major effort has been directed toward identifying and characterizing the adhesion glycoproteins that enable leukocytes to bind to vascular endothelial cells. Drugs that specifically target adhesion molecules involved in leukocyte recruitment are effective in treating intestinal inflammation.

    They said that experimental models have shown that blockade of VLA-4, VCAM-1 and P-selectin afford significant amelioration of intestinal inflammation. In experimental models, response to adhesion molecule blockage varies according to the type of inflammatory intestinal condition. In humans VLA-4 immunoneutralization has been effective in inducing remission in Crohn's Disease, but no data is available for ulcerative colitis.

    The researchers call for experimental and clinical controlled trials comparing the effectiveness of different strategies of CAM blockade, and suggest that this therapeutic approach be compared with current therapies.

  • Platelet recruitment in intestinal inflammation modulated by ICAM-1, P-selectin, PSGL-1

    Researchers from LSU and the University of Muenster studied the mechanisms responsible for platelet-WBC and platelet-endothelial cell (EC) interactions that occur in exper
    '"/>



    • Contact: Mayer Resnick
    mresnick@the-aps.org
    301-634-7209
    American Physiological Society
    9-Sep-2004


    Page: 1 2 3

    Related biology news :

    1. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
    2. Novel approaches to current cellular therapies continue progress toward disease prevention
    3. Novel therapies show promise against myeloid leukemia
    4. Novel sensors help clear the air
    5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
    6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
    7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
    8. Novel bacterium detoxifies chlorinated pollutants
    9. Novel flu vaccine shows promise in mice
    10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
    11. Novel method identifies hidden genes

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:8/26/2020)... SAN DIEGO and SHANGHAI (PRWEB) , ... August ... ... company pursuing novel approaches for the treatment of chronic inflammatory and fibrotic diseases, ... Operating Officer and Vice President of Drug Discovery. , Dr. Canan previously served ...
    (Date:8/21/2020)... LEXINGTON, Mass. (PRWEB) , ... August 18, 2020 ... ... novel approaches to cell therapy, today announced that the U.S. Food and Drug ... evaluation of Sentien’s lead asset, SBI-101, for the treatment of severe COVID-19. Approval ...
    (Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently announced ... for public health agencies of all sizes. With a focus on tracking symptoms ... find appropriate health care, Mosio helps public health departments automate communications and provide ...
    Breaking Biology News(10 mins):
    (Date:7/22/2020)... , ... July 22, 2020 , ... Join experts from ... Lorenc, Sr. Manager Regulatory Solutions, in a one hour live webinar on ... regulating body in China for drugs and medical devices. Specifically, for medical devices, the ...
    (Date:7/18/2020)... TORONTO (PRWEB) , ... July 17, 2020 , ... ... and global consulting firm for the life sciences and food industries, is pleased ... new Director of Clinical Research – Business Development. , Charles is an accomplished ...
    (Date:7/10/2020)... ... July 09, 2020 , ... ... therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its ... the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves as ...
    (Date:7/1/2020)... ... June 29, 2020 , ... The Interlocal Purchasing ... to its membership, recently named BioFit Engineered Products an Awarded Vendor. ... purchase ergonomic seating, cafeteria tables, book trucks and carts at discounted pricing without ...
    Breaking Biology Technology:
    Cached News: